Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Vanderbilt
With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?
Related Questions
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
Does anyone have experience obtaining sunvozertinib in the second line setting for patients with EGFR exon 20 insertion mutations?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
